Michael Deel

Michael D. Deel, MD


  • Member, Solid Tumor Oncology Team
  • Associate Professor, UC Department of Pediatrics
I strive to create a supportive environment where patients feel empowered, heard and actively involved in their treatment decisions.
Michael D. Deel, MD

About

Biography

I am a pediatric and young adult oncologist specializing in the treatment of solid tumors such as sarcoma and neuroblastoma. My practice aims to provide personalized care that encompasses medical treatments, emotional support, and open communication for patients and families. With a background in engineering, I bring a problem-solving mindset to finding innovative solutions for complex medical challenges.

Dedicated to providing compassionate care, support, and guidance to patients and their families facing the immense stresses associated with cancer diagnoses and treatments, I aim to provide holistic care by treating the cancers while also prioritizing each patient's overall well-being and quality of life. I strive to create a supportive environment where patients feel empowered, heard and actively involved in their treatment decisions. I’m committed to minimizing the time spent in the hospital whenever possible, as it is crucial for patients to have opportunities for normalcy as they engage in activities they enjoy.

My research focuses on understanding the molecular machinery of tumors in order to identify vulnerabilities that can be targeted with novel therapies. I address issues such as drug resistance and toxicity, with the ultimate goal of improving survival along with enhancing the quality of life for cancer patients.

Before joining Cincinnati Children's in 2024, I dedicated 11 years of my career to Duke University, where I focused on identifying new vulnerabilities for targeting difficult-to-treat sarcomas. My work was recognized with a Fellowship Award from the St. Baldrick's Foundation (2016), a Young Investigator Award from the National Pediatric Cancer Foundation (2021), Scholar Awards from both the V Foundation (2018) and Hyundai Hope on Wheels (2021), as well as a Career Development Award from the U.S Department of Defense (2023).

Undergrad: Engineering, Virginia Tech, Blacksburg, VA, 2002.

MD: Marshall University School of Medicine, Huntington, WV, 2010.

Residency: Pediatrics, University of Louisville, Louisville, KY, 2013.

Fellowship: Pediatric Hematology/Oncology, Duke University, Durham, NC, 2016.

Certification: General Pediatrics, 2013; Pediatric Hematology/Oncology, 2017.

Interests

Cancer and blood diseases; adolescent and young adult cancer; sarcoma; neuroblastoma; solid tumors

Services and Specialties

Cancer and Blood Diseases

Interests

Investigating new therapeutic approaches for difficult to treat sarcomas and other solid tumors

Research Areas

Cancer and Blood Diseases

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

Pediatric spindle cell/sclerosing rhabdomyosarcoma with FUS-TFCP2 fusion: a case report and literature review. Fang, Z; Duan, C; Wang, S; Fu, L; Yang, P; Yu, T; Deel, MD; Lau, LM S; Ma, X; Ni, X; Su, Y. Translational Pediatrics. 2024; 13:178-191.

Oncology of childhood and adolescence. Mangoli, A; Bellantoni, AJ; Deel, MD. Encyclopedia of Child and Adolescent Health. : Elsevier; Elsevier; 2023.

Hematology of childhood and adolescence. Bellantoni, AJ; Mangoli, A; Deel, MD. Encyclopedia of Child and Adolescent Health. : Elsevier; Elsevier; 2023.

More Than Meets the Eye? A Cautionary Tale of Malignant Ectomesenchymoma Treated as Low-risk Orbital Rhabdomyosarcoma. Rashid, T; Bagatell, R; Pawel, B; Bentley, RC; Kreissman, SG; Deel, MD. Journal of Pediatric Hematology/Oncology. 2021; 43:e854-e858.

Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children's Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force. Pacenta, HL; Allen-Rhoades, W; Langenau, D; Houghton, PJ; Keller, C; Heske, CM; Deel, MD; Linardic, CM; Shern, JF; Stewart, E; Chen, EY; Amatruda, JF; Hingorani, P; Laetsch, TW. Journal of Clinical Medicine. 2021; 10:1416.

Advances in the Diagnosis and Management of Neonatal Sarcomas. Rashid, T; Noyd, DH; Iranzad, N; Davis, JT; Deel, MD. Clinics in Perinatology. 2021; 48:117-145.

A method to culture human alveolar rhabdomyosarcoma cell lines as rhabdospheres demonstrates an enrichment in stemness and Notch signaling. Slemmons, KK; Deel, MD; Lin, YT; Oristian, KM; Kuprasertkul, N; Genadry, KC; Chen, PH; Chi, JT A; Linardic, CM. Biology Open. 2021; 10:bio050211.

Advances in the management of pediatric genitourinary rhabdomyosarcoma. Deel, MD. Translational Andrology and Urology. 2020; 9:2441-2454.

RASSF4 is required for skeletal muscle differentiation. Lin, YT; Deel, MD; Linardic, CM. Cell Biology International. 2020; 44:381-390.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey

4.6
Overall Patient Rating